Studying TAK-243 in Patients With Advanced Cancer (NCT06223542)
🩺 Plain-English Summary (8th-Grade Level)
This phase I trial studies the side effects and best dose of ubiquitin-activating enzyme (UAE) inhibitor TAK-243 (TAK-243) in treating patients with a solid tumor that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic) and in patients with lymphoma. TAK-243 is a drug that binds to and inhibits the ubiquitin-activating enzyme, an enzyme that is more active on cancer cells than healthy cells, inhibiting tumor cell proliferation and survival.
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (24 items) and avoid the listed exclusions (38 items).
Location: National Cancer Institute Developmental Therapeutics Clinic — Bethesda, Maryland
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion Criteria:
- Patients who are receiving any other investigational agents
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection or psychiatric illness/social situations that would limit compliance with study requirements
- Life-threatening illness unrelated to cancer
- Patients with uncontrolled coagulopathy or bleeding disorder
- Known hepatic cirrhosis or severe pre-existing hepatic impairment
- Known cardiopulmonary disease defined as:
- Unstable angina pectoris;
- Congestive heart failure (New York Heart Association \[NYHA\] class III or IV);
- Myocardial infarction (MI) within 6 months prior to first dose (patients who had ischemic heart disease such as a \[acute coronary syndrome (ACS)\], MI, and/or revascularization greater than 6 months before screening and who are without cardiac symptoms may enroll);
- Cardiomyopathy
- Clinically significant arrhythmia:
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (1 Sites)
- National Cancer Institute Developmental Therapeutics Clinic — Bethesda, Maryland
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.